ZEISS creates a compelling new way of envisioning the neurosurgical workflow using the building blocks of existing and new technologies. Five renowned surgeons will talk about how market-leading technologies come together to provide a comprehensive toolset to See, Check and Treat patients with brain tumors. Please join us in hearing from Dr. Walavan Sivakumar, Dr. Peter Nakaji, Dr. Jennifer Eschbacher, Dr. Christopher Cifarelli and Dr. Klaus-Henning Kahl on various solutions available from ZEISS.
Walavan Sivakumar, MD, is a fellowship-trained neurosurgeon with a focus on skull base and minimally invasive and endoscopic neurosurgery. Dr. Sivakumar has a particular interest and expertise in brain tumors, skull base tumors, pituitary/parasellar tumors, and intraventricular brain tumors, and he applies the keyhole concept, utilizing advanced neuroimaging and microsurgical techniques to minimize collateral damage to the brain. He serves as the Director of Neurovascular Surgery at the Pacific Neuroscience Institute and Director of Neurosurgery at Providence Little Company of Mary Medical Center. Dr. Sivakumar has over 50 peer-reviewed publications, largely focused on brain tumor biology and skull base surgery outcomes.
Award highlights include the William H. Sweet Award from the American Association of Neurological Surgeons (AANS), Stryker Neuro-Oncology Award from the Congress of Neurological Surgeons (CNS), and best research awards from the Rocky Mountain Neurosurgical Society (RMNS) and Western Neurosurgical Society (WNS). He completed his residency training in Salt Lake City at the University of Utah, and his fellowship in Endoscopic Skull Base and Pituitary Surgery and Minimally Invasive Neurosurgery with Dr. Daniel Kelly at the John Wayne Cancer Institute.
Dr. Sivakumar is an active member of the AANS and CNS, currently serving as the secretary on the AANS Young Neurosurgeons Committee and executive committee of the AANS/CNS Section on Tumors. He has a deep interest in neurosurgical trainee education and is involved in the Clinical/Research Neurosurgical Fellowship at the John Wayne Cancer Institute.
Peter Nakaji, MD, is an internationally known neurosurgeon, who has published more than 200 peer-reviewed papers and holds more than two dozen patents.
Dr. Nakaji has received a number of teaching awards and has served for nearly a decade as the program director for the Neurosurgery residency at Barrow Neurological Institute. In his role as department chair at Banner Health, Dr. Nakaji extends neuroscience training for medical students, residents and fellows.
In addition to treating complex diseases of the brain, Dr. Nakaji is a pioneer in the area of neuroendoscopy for “keyhole” treatment of conditions such as trigeminal neuralgia and colloid cysts. He has a passion for technically demanding brain surgery and is a respected authority in the treatment of aneurysms, arteriovenous malformations, cavernous malformations, moyamoya disease, extracranial-intracranial bypass, carotid artery disease, as well as brain and skull base tumors.
Dr. Nakaji completed his residency at the University of California – San Diego. He received additional fellowship training in endoscopic neurosurgery at the Centre for Minimally Invasive Neurosurgery in Sydney, Australia, under the direction of Charles Teo, MD. He completed a second fellowship in cerebrovascular and skull base surgery at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix under Robert Spetzler, MD, before joining the staff as an attending neurosurgeon in 2004.
Jennifer Eschbacher, MD, is a board certified neuropathologist and surgical pathologist at St. Joseph’s Medical Center/ Barrow Neurological Institute. In addition to her work as a pathologist, she is the laboratory director for the Ivy Brain Tumor Center and principal investigator for the biobank core facility.
Christopher Cifarelli, MD, PhD, received his medical training at Jefferson Medical College in Philadelphia, PA where he also earned his PhD in Developmental Biology & Teratology, followed by a residency in Neurological Surgery at the University of Virginia in Charlottesville, VA.
He currently holds the rank of Associate Professor of Neurosurgery and Radiation Oncology at West Virginia University where he has served as the Director of the Radiosurgery Program since 2014. In that role, he has advanced the Gamma Knife Center to the status of a Center of Excellence through the International Radiosurgery Research Foundation and developed the Intra-operative Radiotherapy practice in collaboration with the Radiation Oncology Department, treating the first GBM patient with IORT on clinical trial in the US in 2017. He serves on the Editorial Board of the Journal of Neuro-Oncology, the Executive Committee of the CNS/AANS Joint Section on Tumors, and a reviewer for the Neurosurgery Research & Education Foundation through the AANS. In addition to his clinical neuro-oncology practice, Dr. Cifarelli runs an NIH-funded research laboratory focused on identifying molecular determinants of radiation sensitivity in glioblastoma.
Klaus-Henning Kahl, MD, is a consultant and the assistant director of the Department of Radio-Oncology and chief of the IORT program at the University. He is head for the setup of the Radiosurgery Unit/SXRT at University Hospital Augsburg, Germany.
His main clinical research topics includes IORT in Neuro-, Breast- and GI-Oncology, also he is driving research on Radio-Immunological Effects of high doses, SRS, HSRT and SABR.
At the University Hospital Augsburg, a collaboration between the various specialist disciplines is made possible by the Interdisciplinary Cancer Center Augsburg ICCA under one roof. Through this interdisciplinary exchange, each patient receives the optimal cancer treatment in close cooperation with the referring doctors.
The statements of the speakers reflect only their personal opinions and do not necessarily reflect the opinions of any institution with which they are affiliated.
The speakers have a contractual or other financial relationship with Carl Zeiss Meditec, Inc. and its affiliates and have received financial support.